Journal Article

DKFZ-2022-02847

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Respiratory and cardiometabolic comorbidities and Stage I-III non-small cell lung cancer (NSCLC) survival: A pooled analysis from the International Lung Cancer Consortium (ILCCO).

García-Pardo, M. ; Chang, A. ; Schmid, S. ; Dong, M. ; Brown, M. C. ; Christiani, D. ; Tindel, H. A. ; Brennan, P. ; Chen, C. ; Zhang, J. ; Ryan, B. M. ; Zaridze, D. ; Schabath, M. B. ; Leal, L. F. ; Reis, R. M. ; Tardon, A. ; Fernández-Tardon, G. ; Shete, S. S. ; Andrew, A. ; Brenner, H.DKFZ* ; Xu, W. ; Hung, R. J. ; Liu, G.

2023
Elsevier Amsterdam

This record in other databases:  

Please use a persistent id in citations: doi:10.1016/j.jtho.2022.10.020

Abstract: We explored the association of respiratory and cardiometabolic comorbidities with NSCLC overall survival (OS) and lung cancer specific survival (LCSS), by stage, in a large, multi-continent NSCLC pooled dataset.Based on patients pooled from 11 ILCCO studies with available respiratory and cardiometabolic comorbidity data, adjusted Hazard Ratios (aHR) were estimated using Cox models for OS. LCSS was evaluated using competing risk Grey and Fine models and cumulative incidence functions. Logistic regression (adjusted odds ratio, aOR) was applied to assess factors associated with surgical resection.OS analyses utilized NSCLC patients with respiratory health or cardiometabolic health data (N=16,354); a subset (N=11,614) contributed to LCSS analyses. In stage I-IIIA NSCLC, patients with respiratory comorbidities had worse LCCS (Stage IA aHR 1.51, CI 1.17-1.95; Stage IB-IIIA aHR 1.20, CI 1.06-1.036). In contrast, stage I-IIIA patients with cardiometabolic comorbidities had a higher risk of death from competing (non-NSCLC) causes (Stage IA aHR 1.34, CI 1.12-1.69). The presence of respiratory comorbidities was inversely associated with having surgical resection (Stage IA aOR 0.54 CI 0.35-0.83; Stage IB-IIIA aOR 0.57, CI 0.46-0.70).The presence of either cardiometabolic or respiratory comorbidities is associated with worse OS in Stage I-III NSCLC. Patients with respiratory comorbidities were less likely to undergo surgery and had worse LCSS, while patients with cardiometabolic comorbidities had a higher risk of death from competing causes. As more treatments options for Stage I-III NSCLC are introduced into practice, accounting for cardiometabolic and respiratory comorbidities becomes essential in trial interpretation and clinical management.

Keyword(s): COPD ; Comorbidity ; NSCLC

Note: Volume 18, Issue 3, March 2023, Pages 313-323

---

Contributing Institute(s):

1. C070 Klinische Epidemiologie und Alternf. (C070)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2022

---

Database coverage:
; Allianz-Lizenz ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---